Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 9, 21-9

Fecal Calprotectin in Inflammatory Bowel Disease


Fecal Calprotectin in Inflammatory Bowel Disease

Natalie E Walsham et al. Clin Exp Gastroenterol.


Inflammatory bowel disease (IBD) and irritable bowel syndrome share many symptoms. While irritable bowel syndrome is a functional bowel disorder for which no specific treatment is available, the range of effective therapies for IBD is evolving rapidly. Accurate diagnosis of IBD is therefore essential. Clinical assessment, together with various imaging modalities and endoscopy, has been the mainstay of diagnosis for many years. Fecal biomarkers of gastrointestinal inflammation have appeared in the past decade, of which calprotectin, a neutrophil cytosolic protein, has been studied the most. Crohn's disease and ulcerative colitis are chronic remitting and relapsing diseases, and objective assessment of disease activity and response to treatment are important. This review focuses on the use of fecal calprotectin measurements in the diagnosis and monitoring of patients with IBD.

Keywords: Crohn’s disease; calprotectin; inflammation; inflammatory bowel disease; ulcerative colitis.


Figure 1
Figure 1
Suggested algorithm for the use of fecal calprotectin in the differentiation of IBS and IBD. Abbreviations: IBS, irritable bowel syndrome; IBD, inflammatory bowel disease; GI, gastrointestinal; NSAIDs, nonsteroidal anti-inflammatory drugs.

Similar articles

See all similar articles

Cited by 30 PubMed Central articles

See all "Cited by" articles


    1. National Institute for Health and Clinical Excellence . NICE diagnostic guideline 11. London UK: 2013. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel.
    1. Fagerhol M, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir. 1980;16(Suppl):273–282. - PubMed
    1. Hsu K, Champaiboon C, Guenther BD, et al. Anti-infective protective properties of S100 calgranulins. Antiinflamm Antiallergy Agents Med Chem. 2009;8:290–305. - PMC - PubMed
    1. Roseth A, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by fecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:276–180. - PubMed
    1. Roseth A, Schmidt P, Fagerhol M. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:50–54. - PubMed